×

Dermatological Drugs Market To See 4.29% CAGR Driven By Pharmaceutical Industry To 2018 : Radiant Insights,Inc

San Francisco, June 20, 2016 (GLOBE NEWSWIRE) -- The dermatological drugs market is estimated to exhibit a 4.29% CAGR over the forecast period (2013-2018). Factors driving the market are the geriatric populace, occurrence of skin diseases (e.g., melanoma), and indoor tanning.

Complete Report Available @ http://www.radiantinsights.com/research/global-dermatological-drugs-market-2014-2018

The latest trend running in the market is biologics. Biologics are substances identical to proteins in our body, which can fight off diseases and strengthen the immune system. Side effects of these drugs could pose a challenge to the market.

Dermatological drugs will gain prominence in the coming years on account of being used for treating psoriasis, acne, and other skin-related conditions. The market is at risk of losing share to generic drugs on the market.

Major applications encompassed under the market are infections, dermatitis, immune disorders, and cancers. People obsessed with their aesthetic appearance due to an overbearing influence of celebrity culture are a major driving factor of the market.

Antifungals, antibacterials, antiallergic products, antivirals, and immunotherapies constitute as major market products. New dermatology products with a primary focus on MEK (Mitogen-activated protein kinase kinase) inhibitors, JAK (Janus Kinase) inhibitors, and monoclonal antibodies are expected to attain market shares in the near future.

Request A Sample Copy Of This Report at: www.radiantinsights.com/research/global-dermatological-drugs-market-2014-2018/request-sample

Prominent manufacturers in the dermatological drugs market are Johnson & Johnson, Pfizer, Inc., Anacor Pharmaceuticals, Inc., and Valeant Pharmaceuticals International. Mergers & acquisitions and introducing novel drugs are strategies adopted by these manufacturers.

In 2012, Mylan N.V. acquired a license to manufacture two major drugs from Valeant Pharmaceuticals. The company has mass-manufactured generic version of dermatological creams (Clindamycin Phosphate/Benzoyl Peroxide Gel), which would let them attain market share with limited competition.

Table of Contents

  1. Executive Summary
  2. List of Abbreviations
  3. Scope of the Report

3.1 Market Overview

3.2 Product Offerings

See More Reports of This Category by Radiant Insights: http://www.radiantinsights.com/catalog/pharmaceutical

  1. Market Research Methodology

4.1 Market Research Process

4.2 Research Methodology

Explore Other Reports By Radiant Insights,Inc at

  • Acute Pain Global Clinical Trials Review –

http://www.radiantinsights.com/research/acute-pain-global-clinical-trials-review-h1-2016

  • Nasal Polyps Global Clinical Trials Review –

http://www.radiantinsights.com/research/nasal-polyps-global-clinical-trials-review-h1-2016

About Radiant Insights

Radiant Insights is a market research and consulting company offering syndicated research studies, customized reports, and consulting services. Our market research studies are designed to facilitate strategic decision making, on the basis of extensive and in-depth quantitative information, supported by extensive analysis and industry insights. Using a patented and robust research methodology, we publish exhaustive research reports covering a host of industries such as Technology, Chemicals, Materials, and Energy.Radiant Insights has a strong base of analysts, consultants and domain experts, with global experience helping us deliver excellence in all research projects we undertake.

Contact Details:

Michelle Thoras

Corporate Sales Specialist, USA

Radiant Insights, Inc

Phone: 1-415-349-0054

Toll Free: 1-888-202-9519

Email: sales@radiantinsights.com

Web: http://www.radiantinsights.com/

Source: Radiant Insights